Prevalence of severe adverse events among health professionals after receiving the first dose of the ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021.

Yao Rodion KonuFifonsi Adjidossi Gbeasor-KomlanviMouhoudine YerimaArnold Junior SadioMartin Kouame TchankoniWendpouire Ida Carine Zida-CompaoreJosée Nayo-ApetsianyiKossivi Agbélénko AfanviSibabe AgoroMounerou SalouDadja Essoya LandohAtany B NyansaEssohanam BokoMoustafa MijiyawaDidier Koumavi Ekouevi

Published in: Archives of public health = Archives belges de sante publique (2021)

High prevalence of SAEs have been observed in health professionals in Togo after ChAdOx1 nCoV-19 vaccination especially in young people and females. However, these data are reassuring as they inform on COVID-19 vaccines' SAE management. Systematic prescription of antalgics or antipyretics could be proposed to young people who get vaccinated.

Keyphrases

sars cov
coronavirus disease
respiratory syndrome coronavirus
risk factors
electronic health record
early onset
big data
machine learning